Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder.
Atomoxetine is a novel, non-stimulant, highly selective noradrenaline reuptake inhibitor that has been studied for use in the treatment of attention deficit/hyperactivity disorder (ADHD). Data from clinical trials show it to be well tolerated and effective in the treatment of ADHD in children, adolescents, and adults. Improvements were seen not only in core symptoms of ADHD, but also in broader social and family functioning and self esteem. Once-daily dosing of atomoxetine has been shown to be effective in providing continuous symptom relief. Atomoxetine does not appear to have abuse potential and is associated with a benign side effect profile. The development of atomoxetine thus represents an important advance in the pharmacological management of ADHD.
Barton
J
J
North Staffordshire Combined Health Care NHS Trust, Moorlands Team, Abbey Hulton Clinic, Leek Road, Stoke-On-Trent, Staffordshire ST2 8BP, UK. Joanne.Barton@nsch-tr.wmids.nhs.uk
D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D004311:Double-Blind Method; D006801:Humans; D011437:Propylamines / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
D011437:Propylamines; D000069445:Atomoxetine Hydrochloride